PEPGEN INC

Company Overview

PepGen Inc. is a clinical‑stage biotechnology company developing peptide‑enabled oligonucleotide therapeutics using its Enhanced Delivery Oligonucleotide (EDO) platform (CPPs conjugated to PMOs) to treat rare neuromuscular/neurologic diseases. Its lead programs were PGN‑EDO51 (DMD) and PGN‑EDODM1 (DM1); PGN‑EDO51 was voluntarily discontinued in May 2025 after dystrophin increases fell short of targets, and the company is reallocating resources to PGN‑EDODM1 (FREEDOM program). PepGen is R&D‑heavy, outsources GMP manufacturing to CDMOs, maintains licensed core IP, operates from a single Boston site with ~81 employees, and has a history of equity financings; cash was $74.7M at 6/30/2025 with management warning of substantial doubt about one‑year going concern funding.

Executive Compensation Practices

Compensation is likely weighted toward equity and milestone‑linked pay given PepGen’s heavy R&D burn, limited commercial revenue and need to conserve cash; management disclosed rising stock‑based compensation (a ~$7.3M year‑over‑year increase) and increased headcount driving G&A. Typical pay elements will include stock options/RSUs, long vesting tied to clinical/regulatory milestones (IND clears, cohort readouts, orphan/fast‑track designations), and retention or sign‑on awards to secure experienced R&D talent. Accounting sensitivity around stock‑based compensation valuation and R&D accruals (highlighted in MD&A) means reported compensation expense and dilution from option exercises/grants can materially affect EPS and cash strategy; executives may accept below‑market cash salaries offset by larger equity grants during capital constrained periods.

Insider Trading Considerations

Insider activity should be watched for timing around clinical milestones, regulatory interactions (e.g., the FDA clinical hold on CONNECT2 and Health Canada queries), and announced financings — PepGen completed a 2024 follow‑on/ATM financing and later faced a program wind‑down and a tightened cash runway, events that commonly precede insider option exercises or sales. Given the small‑cap, binary nature of trial readouts and the company’s reliance on future financings, look for patterns such as directors/executive option exercises followed by immediate share sales, Section 16 filings, and use of 10b5‑1 plans that can signal planned liquidity vs. opportunistic trading. Regulatory blackout periods around material nonpublic clinical data and heightened SEC scrutiny in healthcare mean that any insider trades near readouts or financing announcements will attract attention from investors and regulators.